Non-Heme Iron Oxygenases Generate Natural Structural Diversity in Carbapenem Antibiotics

Micah J. Bodner, **Ryan M. Phelan**, **Michael F. Freeman**, **Rongfeng Li**, and **Craig A. Townsend**[*]

Department of Chemistry, Johns Hopkins University, 3400 N. Charles St. Baltimore, MD 21218

Carbapenem antibiotics are of clinical importance because of their high potency, broad spectrum of antimicrobial activity and resistance to most β-lactamases.[1] Thienamycin (**1**) (Figure 1), the most potent natural member of this family, co-occurs in *Streptomyces cattleya* with four carbapenems that are distinguished by their C-2/C-6 substituents.[2] There are more than 50 known carbapenam/em metabolites, many of which are differentiated only by the oxidation state of their C-2/C-6 substituents. The C-6 ethyl side chain of **1** is derived by C^1- donations from methionine[3,4] and can be methyl, ethyl or isopropyl, which can be saturated, unsaturated, hydroxylated or sulfated. Recent work has established that coenzyme A is successively truncated by three enzymes encoded by the thienamycin gene cluster, to give the C-2 cysteamine moiety.[5] This side chain can be pantetheine, but is generally cysteamine, which can be *N*-acetylated or *N*-propionylated, desaturated and further oxidized to the sulfoxide, or cleaved and oxidized in a stepwise fashion to the sulfonic acid. These carbapenem metabolites comprise a natural combinatorial library whose structural modifications temper the high intrinsic hydrolytic instability of the carbapenem nucleus, as well as affect the antimicrobial spectrum and β-lactamase resistance of each family member.[1] Some of the higher oxidation state carbapenems have either enhanced antibiotic activity or increased β-lactamase resistance, and so, in the broad context of carbapenem biosynthesis, the origin of this oxidative diversity is of particular interest.

The variability of carbapenem side chain oxidation state as well as the discovery of a mutant strain[6] of *Streptomyces cattleya* that produced deshydroxy thienamycin (**10**) instead of thienamycin (**1**) led us to believe that the thienamycin gene cluster[7] encoded one or more enzyme(s) capable of oxidizing the C-2/C-6 moieties of carbapenems. Protein sequence analysis of ThnG and ThnQ indicated that each enzyme contained the $Hx(D/E)x_nH$ motif characteristic of non-heme Fe(II)/α-ketoglutarate (α-KG)–dependent dioxygenases, and these seemed promising candidates.[8] However, ThnG and ThnQ are in the same family as CarC encoded by the (5R)-carbapenem-3-carboxylate (**13**) gene cluster in *Pectobacterium carotovorum*.[9,10] Despite low homology to CarC, ThnG and ThnQ have been postulated to catalyze steps in thienamycin biosynthesis analogous to the coupled C-5 epimerization and C-2/C-3 desaturation of (2S,5S)-carbapenam (**11**) to (5R)- carbapenem-3-carboxylate (**13**) catalyzed by CarC.[11] To discern their roles in thienamycin biosynthesis, ThnG and ThnQ were analyzed for carbapenem-oxidizing activity, as well as for the ability to catalyze C-5 epimerization and coupled or uncoupled C-2/C-3 desaturation of carbapenams/ems.

The envisioned experiments required carbapenam/ems varying in stereochemical configuration at C-6 as well as C-2/C-6 oxidation state/substitution pattern to serve as

*ctownsend@jhu.edu.

Supporting Information Available: Experimental procedures, HPLC comparisons and compound characterizations are available via the internet at http://pubs.acs.org.

substrates and reference standards. Two methods were employed to establish the C-6 substituent and C-5/C- configuration by synthesizing precursor azetidinones. The first method provided the *trans* (3*S*,4*R*)-configuration by alkylating the enolate of an azetidinone derived from L-aspartic acid.[12] The second method employed a catalytic asymmetric azetidinone-forming reaction that produced either enantiomer of the *cis* 3,4-disubstituted azetidinones with independent control of the carbapenem C-8 sterocenter.[13] These compounds could be used as precursors of *cis* or *trans* carbapenems. Azetidinones were converted to carbapenems by the Merck method, which allowed various C-2 groups to be introduced.[14,15] The intermediate 2-oxocarbapenams in this route can be reduced and directed to the preparation of carbapenams bearing thioether substituents at C-2 (Figure 1c).[5] Carbapenam thioethers **14–17**, (2*S*,5*S*)-carbapenam (**11**), (2*S*,5*R*)-carbapenam (**12**)[16] and 5-*epi*-PS-5 **6** were synthesized to test ThnG and ThnQ for coupled or uncoupled carbapenam ring epimerization and desaturation. PS-5 (**5**) was synthesized to test for side chain oxidation activity, because the acetylated cysteaminyl side chain is more stable than the unacetylated deshydroxy thienamycin (**10**). PS-7 (**7**), PS-7 sulfoxide (**9**), PS-5 sulfoxide (**8**), *N*-acetyl thienamycin (**2**) and the diastereomeric mixture (8*S*,*R*)-*N*-acetyl thienamycin (**4**) were synthesized as additional substrates and reference standards.

Thienamycin biosynthetic cluster genes *thnG* and *thnQ* were cloned from genomic DNA and inserted into pET29b each bearing a *C*-terminal His$_6$-tag. The recombinant proteins were over-produced in *E. coli* Rosetta2(DE3) and purified by Ni-NTA affinity chromatography. *In vitro* reactions in MOPS, pH 7.0, containing Fe(NH$_4$)$_2$(SO$_4$)$_2$, α-KG, ascorbate, the subject carbapenam/em and either ThnG or ThnQ were incubated and analyzed by HPLC for the formation of new product(s).[17,18] Clear outcomes were observed for both ThnG- and ThnQ-catalyzed reactions with PS-5 (**5**) (Figure 2 and Supporting Information). The products were immediately identifiable as carbapenems by their unique chromophores (λ_{max} = 290–320 nm). ThnQ produced a single new product more polar than **5**, while ThnG produced two products one with a shorter retention time and one with a longer retention time than **5**.

ESI mass spectrometric analysis of the new product (*m/z* = 313.05) in the ThnQ-catalyzed reaction established that a single oxygen had been incorporated. Its identity was determined by co-injection with *N*-acetyl thienamycin (**2**) and (8*S*,*R*)-*N*-acetyl thienamycin **4** (Fig. 2d,e, S3). This HPLC comparison demonstrated that ThnQ stereospecifically hydroxylated PS-5 (**5**) to produce **2**. The chromatographically distinct (8*S*)-*N*-acetyl thienamycin diastereomer was not detected (Fig. S4). ESI-MS analysis of the products of the ThnG-catalyzed reaction with **5** indicated that the late eluting product (*m/z* = 295.05) had an additional degree of unsaturation relative to **5**, and the early eluting product (*m/z* = 311.15) was both desaturated and oxidized. The carbapenems were identified as PS-7 (**7**) and PS-7 sulfoxide **9** by HPLC comparison to synthetic standards (Fig. 2a–c, S5). ThnG was also able convert **7** to its sulfoxide, but unable to catalyze desaturation when given PS-5 sulfoxide **8**, indicating that desaturation precedes sulfoxidation (Fig. S6).

The oxidative relationships among carbapenems was further demonstrated by conversion of PS-7 (**7**) and *N*-acetyl thienamycin (**2**) into the *S. cattleya* metabolite *N*-acetyl dehydro thienamycin (**3**). Upon reaction with **2**, ThnG produced a less polar product and ESI-MS indicated it contained an additional degree of unsaturation. ThnQ produced a more polar product on reaction with **7**. These new products co-eluted under HPLC, had identical masses by ESI-MS and were assigned the same structure, *N*-acetyl dehydrothienamycin (**3**). Notably no sulfoxide product was observed consistent with the metabolite profile in *S. cattleya* and suggesting that ThnQ reaction precedes that of ThnG.

HPLC analyses of other carbapenam/ems (**6**, **11**, **12**, **14–17**) tested with ThnG and ThnQ did not show appearance of a carbapenem chromophore or other new products. Additionally, *in*

vitro reactions with carbapenam/ems (**6**, **11**, **12, 14–17**) employing cell free extracts harboring ThnG or ThnQ were analyzed with the super-sensitive *E. coli* SC 12155, and the Nitrocefin β-lactamase induction assay using *Bacillus licheniformis* ATCC 14580.[19,20] By none of these three sensitive measures could antibiotic production be detected.

These experiments demonstrate that the Fe(II)/α-KG-dependent oxygenases ThnG and ThnQ oxidize the C-2 and C-6 side chains, respectively, of carbapenem substrates. No evidence was found that they catalyze coupled or uncoupled C-5 epimerization and/or C-2/C-3 desaturation in the carbapenam/ems tested. On these bases it appears that the latter two reactions rely on other proteins encoded by the thienamycin gene cluster that are distinct from the non-heme iron oxygenases like CarC, key to the biosynthesis of (5*R*)-carbpenem-3-carboxylate (**13**).[10, 11,21] Oxidative modifications of the C-2 and C-6 side chains of carbapenems are major determinants of their antimicrobial spectrum and β-lactamase resistance. These activities strongly suggest that the known carbapenems produced by *S. cattleya* arise from ThnG and ThnQ oxidation of a common biosynthetic precursor, and that much of the structural diversity exemplified by this class of antibiotics likely derives from orthologs present in other carbapenem producers. Knowledge of these oxidative relationships will more sharply refine further biosynthetic investigations of this antibiotic family.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

References

1. Bonfiglio G, Russo G, Nicoletti G. Expert Opin Inv Drug 2002;11(4):529–544.

2. Wilson KE, Kempf AJ, Liesch JM, Arison BH. J Antibiot 1983;36(9):1109–1117. [PubMed: 6630073]

3. Houck DR, Kobayashi K, Williamson JM, Floss HG. J Am Chem Soc 1986;108(17):5365–5366.

4. Williamson JM, Inamine E, Wilson KE, Douglas AW, Liesch JM, Albersschonberg G. J Biol Chem 1985;260(8):4637–4647. [PubMed: 3988730]

5. Freeman MF, Moshos KA, Bodner MJ, Li RF, Townsend CA. Proc Natl Acad Sci 2008;105(32): 11128–11133. [PubMed: 18678912]

6. Rosi D, Drozd ML, Kuhrt MF, Terminiello L, Came PE, Daum SJ. J Antibiot 1981;34(3):341–343. [PubMed: 7275813]

7. Nunez LE, Mendez C, Brana AF, Blanco G, Salas JA. Chem Biol 2003;10(4):301–311. [PubMed: 12725858]

8. Hausinger RP. Crit Rev Biochem Mol 2004;39(1):21–68.

9. McGowan SJ, Sebaihia M, Porter LE, Stewart GSAB, Williams P, Bycroft BW, Salmond GPC. Mol Microbiol 1996;22(3):415–426. [PubMed: 8939426]

10. Li RF, Stapon A, Blanchfield JT, Townsend CA. J Am Chem Soc 2000;122(38):9296–9297.

11. Hamed RB, Batchelar ET, Mecinovic J, Claridge TDW, Schofield CJ. Chembiochem 2009;10(2): 246–250. [PubMed: 19090510]

12. Reider PJ, Grabowski EJJ. Tetrahedron Lett 1982;23(22):2293–2296.

13. Bodner MJ, Phelan RM, Townsend CA. Org Lett 2009;11(16):3606–3609. [PubMed: 19610642]

14. Salzmann TN, Ratcliffe RW, Christensen BG, Bouffard FA. J Am Chem Soc 1980;102(19):6161–6163.

15. Ueda Y, Roberge G, Vinet V. Can J Chem 1984;62(12):2936–2940.

16. Stapon A, Li RF, Townsend CA. J Am Chem Soc 2003;125(51):15746–15747. [PubMed: 14677956]

17. Salowe SP, Marsh EN, Townsend CA. Biochemistry 1990;29(27):6499–6508. [PubMed: 2207091]

18. Decristoforo G. Anal Chim Acta 1984;163(SEP):25–33.

19. Sykes RB, Wells JS. J Antibiot 1985;38(1):119–121. [PubMed: 3871760]

20. Gerratana B, Stapon A, Townsend CA. Biochemistry 2003;42(25):7836–7847. [PubMed: 12820893]

21. Stapon A, Li RF, Townsend CA. J Am Chem Soc 2003;125(28):8486–8493. [PubMed: 12848554]

a)

		R	R$_1$	R$_2$
1	thienamycin	(R) H	(R) CHOHCH$_3$	SCH$_2$CH$_2$NH$_2$
2	N-acetyl thienamycin	(R) H	(R) CHOHCH$_3$	SCH$_2$CH$_2$NHAc
3	N-acetyl dehydro thienamycin	(R) H	(R) CHOHCH$_3$	trans-SCHCHNHAc
4	(8S,R)-N-acetyl thienamycin	(R) H	(S,R) CHOHCH$_3$	SCH$_2$CH$_2$NHAc
5	PS-5	(R) H	CH$_2$CH$_3$	SCH$_2$CH$_2$NHAc
6	5-epi-PS-5	(S) H	CH$_2$CH$_3$	SCH$_2$CH$_2$NHAc
7	PS-7	(R) H	CH$_2$CH$_3$	trans-SCHCHNHAc
8	PS-5 sulfoxide	(R) H	CH$_2$CH$_3$	S(O)CH$_2$CH$_2$NHAc
9	PS-7 sulfoxide	(R) H	CH$_2$CH$_3$	trans-S(O)CHCHNHAc
10	deshydroxy thienamycin	(R) H	CH$_2$CH$_3$	SCH$_2$CH$_2$NH$_2$

1-10 R$_3$ = H
1a-10a R$_3$ = PNB

b)

$$11 \xrightarrow{\text{CarC}} 12 \xrightarrow{\text{CarC}} 13$$

c)

	R	R$_1$
(+/-) **14**	H	(S) SCH$_2$CH$_2$NHAc
(+/-) **15**	H	(R) SCH$_2$CH$_2$NHAc
16	CH$_2$CH$_3$	(S) SCH$_2$CH$_2$NHAc
17	CH$_2$CH$_3$	(R) SCH$_2$CH$_2$NHAc

Figure 1.
(a) Representative carbapenems. (b) The CarC catalyzed reaction. (c) Carbapenam thioethers synthesized in this study.

Figure 2.
HPLC analysis of ThnG and ThnQ reactions with PS-5 (**5**). (a) PS-7 sulfoxide diasteriomers
(**9**) standard. (b) PS-7 standard (**7**). (c) ThnG-catalyzed reaction with **5**. (d) *N*-acetyl
thienamycin standard (**2**). (e) ThnQ-catalyzed reaction with **5**.